{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:41:10Z","timestamp":1794865270629,"version":"4.9.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.xcrm.2025.102076","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T10:56:33Z","timestamp":1744714593000},"page":"102076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evolution of the tumor immune landscape during treatment with tebentafusp, a T\u00a0cell receptor-CD3 bispecific"],"prefix":"10.1016","volume":"6","author":[{"given":"Joseph J.","family":"Sacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-2090","authenticated-orcid":false,"given":"Peter","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Britton-Rivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"de la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stanhope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koustubh","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102076_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102076_bib2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.2014.417","article-title":"Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing","volume":"111","author":"Kalirai","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib3","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102076_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.xcrm.2025.102076_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000334576","article-title":"Uveal Melanoma: The Inflammatory Microenvironment","volume":"4","author":"Bronkhorst","year":"2012","journal-title":"J.\u00a0Innate Immun."},{"key":"10.1016\/j.xcrm.2025.102076_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/eye.2012.253","article-title":"Inflammation in uveal melanoma","volume":"27","author":"Bronkhorst","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.xcrm.2025.102076_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/cancers11081132","article-title":"HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target","volume":"11","author":"Souri","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102076_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol. Immunother. : CII"},{"key":"10.1016\/j.xcrm.2025.102076_bib9","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3390\/cancers13143426","article-title":"Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases","volume":"13","author":"Szeligo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102076_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030879","article-title":"The Role of Immune Checkpoint Blockade in Uveal Melanoma","volume":"21","author":"Wessely","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102076_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","article-title":"Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2025.102076_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti\u2013PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib13","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.xcrm.2025.102076_bib14","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","volume":"8","author":"Hoefsmit","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41467-020-15606-0","article-title":"Molecular profiling of driver events in metastatic uveal melanoma","volume":"11","author":"Karlsson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102076_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41467-019-14256-1","article-title":"Single-cell analysis reveals new evolutionary complexity in uveal melanoma","volume":"11","author":"Durante","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102076_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000513336","article-title":"Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy","volume":"7","author":"Orloff","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.xcrm.2025.102076_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000508383","article-title":"Clinical Trials in Metastatic Uveal Melanoma: Current Status","volume":"6","author":"Sussman","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.xcrm.2025.102076_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","article-title":"Tebentafusp for the treatment of HLA-A\u221702:01\u2013positive adult patients with unresectable or metastatic uveal melanoma","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.xcrm.2025.102076_bib20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102076_bib21","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102076_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","article-title":"ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells","volume":"63","author":"Bossi","year":"2014","journal-title":"Cancer Immunol"},{"key":"10.1016\/j.xcrm.2025.102076_bib23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102076_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T\u00a0cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2025.102076_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102076_bib26","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s12094-023-03126-4","article-title":"Targeting CXCL9\/10\/11\u2013CXCR3 axis: an important component of tumor-promoting and antitumor immunity","volume":"25","author":"Pan","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.xcrm.2025.102076_bib27","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102076_bib28","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102076_bib29","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102076_bib30","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102076_bib31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","article-title":"Prognostic impact of B-cell density in cutaneous melanoma","volume":"60","author":"Lad\u00e1nyi","year":"2011","journal-title":"Cancer Immunol. Immunother. : CII"},{"key":"10.1016\/j.xcrm.2025.102076_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102076_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102076_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/jir.2010.0110","article-title":"Interferon-Stimulated Gene 15 and the Protein ISGylation System","volume":"31","author":"Zhang","year":"2011","journal-title":"J.\u00a0Interf. Cytokine Res."},{"key":"10.1016\/j.xcrm.2025.102076_bib35","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/molecules28031337","article-title":"The Functional Roles of ISG15\/ISGylation in Cancer","volume":"28","author":"Yuan","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2025.102076_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12020153","article-title":"Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers","volume":"12","author":"\u00c1lvarez","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.xcrm.2025.102076_bib37","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.1114981109","article-title":"Systematic identification of type I and type II interferon-induced antiviral factors","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xcrm.2025.102076_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/09273940490518586","article-title":"Immunology of intraocular tumors","volume":"13","author":"Niederkorn","year":"2005","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.xcrm.2025.102076_bib39","article-title":"Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy","volume":"8","author":"Qin","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2767-9764.CRC-22-0490","article-title":"Chemokine analysis in patients with metastatic uveal melanoma suggests a role for CCL21 signaling in combined epigenetic therapy and checkpoint immunotherapy","volume":"3","author":"Sah","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.xcrm.2025.102076_bib41","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102076_bib42","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102076_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.xcrm.2025.102076_bib44","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","article-title":"Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities","volume":"129","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib45","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102076_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2004","article-title":"Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity","volume":"4","author":"Snyder","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102076_bib47","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91705.3","article-title":"Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases","volume":"12","author":"Karlsson","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2025.102076_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/eji.200425828","article-title":"Inverse correlation between IL-7 receptor expression and CD8 T\u00a0cell exhaustion during persistent antigen stimulation","volume":"35","author":"Lang","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102076_bib49","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1200\/JCO.2022.40.16_suppl.9585","article-title":"Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM)","volume":"40","author":"Sullivan","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102076_bib50","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T\u00a0cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102076_bib51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"176","author":"Sade-Feldman","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102076_bib52","doi-asserted-by":"crossref","first-page":"13759","DOI":"10.1073\/pnas.212214999","article-title":"IL-2 negatively regulates IL-7 receptor \u03b1 chain expression in activated T lymphocytes","volume":"99","author":"Xue","year":"2002","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.xcrm.2025.102076_bib53","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.4049\/jimmunol.175.9.5895","article-title":"Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8\u00a0T Cell Subsets","volume":"175","author":"Willinger","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2025.102076_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T\u00a0cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102076_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304319120","article-title":"IL-7R licenses a population of epigenetically poised memory CD8+ T\u00a0cells with superior antitumor efficacy that are critical for melanoma memory","volume":"120","author":"Micevic","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xcrm.2025.102076_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41420-022-01101-6","article-title":"Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xcrm.2025.102076_bib57","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102076_bib58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102076_bib59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ccell.2022.06.008","article-title":"New epigenetic regulators of T\u00a0cell exhaustion","volume":"40","author":"Kissick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102076_bib60","doi-asserted-by":"crossref","first-page":"S854","DOI":"10.1016\/j.annonc.2021.08.1397","article-title":"1013P Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy","volume":"32","author":"Piulats","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102076_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205491","article-title":"An approved in\u00a0vitro approach to preclinical safety and efficacy evaluation of engineered T\u00a0cell receptor anti-CD3 bispecific (ImmTAC) molecules","volume":"13","author":"Harper","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102076_bib62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol"},{"key":"10.1016\/j.xcrm.2025.102076_bib63","doi-asserted-by":"crossref","first-page":"S875","DOI":"10.1016\/j.annonc.2022.07.854","article-title":"728O Results from phase I dose escalation of IMC-F106C, the first PRAME\u00a0\u00d7\u00a0CD3 ImmTAC bispecific protein in solid tumors","volume":"33","author":"Hamid","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102076_bib64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnetJ"},{"key":"10.1016\/j.xcrm.2025.102076_bib65","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102076_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102076_bib67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.xcrm.2025.102076_bib68","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102076_bib69","article-title":"Calling Somatic SNVs and Indels with Mutect2","author":"Benjamin","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2025.102076_bib70","series-title":"Genomics in the Cloud: Using Docker, GATK, and WDL in Terra","author":"Van der Auwera","year":"2020"},{"key":"10.1016\/j.xcrm.2025.102076_bib71","first-page":"13","article-title":"PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code Biol","volume":"11","author":"Riester","year":"2016","journal-title":"Med."},{"key":"10.1016\/j.xcrm.2025.102076_bib73","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102076_bib74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS A J. Integr. Biol."},{"key":"10.1016\/j.xcrm.2025.102076_bib76","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2025.102076_bib75","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.xcrm.2025.102076_bib72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/CCI.19.00130","article-title":"Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data","volume":"4","author":"Oh","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.xcrm.2025.102076_bib77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database Hallmark Gene Set\u00a0Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:39:06Z","timestamp":1769056746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666379125001491"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102076","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T\u00a0cell receptor-CD3 bispecific","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102076"}}